Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide. In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). […]
The FDA approved of new drug, Wegovy, to be sold in the U.S. and marketed for weight loss. The drug has been modified from Novo Nordisk s diabetes drug semaglutide.
Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration
Global Parkinson s Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis
April 27, 2021 06:28 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
The global PD market is forecast to experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products.
The highest selling drugs are expected to be: Roche/Prothena s PRX-002 followed by Novo Nordisk s Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.
Global Parkinson s Disease Drug Forecast and Market Analysis to 2029: High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.